| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -224,370 | -142,195 |
| Stock-based compensation expense | 45,451 | 29,649 |
| Lease impairment charge | 3,855 | 0 |
| Depreciation and amortization | 6,281 | 4,132 |
| Premiums and discounts on available-for-sale marketable securities | -6,834 | -4,646 |
| Prepaid expenses and other current assets | 2,039 | 2,305 |
| Accounts receivable | 0 | 40,000 |
| Contract asset | -947 | -947 |
| Other non-current assets | -4,878 | -2,725 |
| Accounts payable | -483 | -216 |
| Accrued expenses and other current liabilities | -6,275 | -6,939 |
| Deferred revenue | 23,660 | 26,424 |
| Operating lease right-of-use assets | -2,070 | -1,362 |
| Operating lease liabilities | -3,713 | -2,416 |
| Other assets and liabilities | -184 | 106 |
| Net cash used in operating activities | -166,144 | -139,034 |
| Purchase of property and equipment, net | 1,343 | 1,162 |
| Purchases of investments | 509,465 | 141,907 |
| Maturities of investments | 384,145 | 251,705 |
| Net cash used in investing activities | -126,663 | 108,636 |
| Issuance of common stock and accompanying pre-funded warrants from january 2024 public offering, net of issuance costs of 14.9 million | 0 | 0 |
| Proceeds from issuance of common stock through at-the market sales agreement, net of issuance costs of 1.2 million | 0 | 0 |
| Issuance of common stock and accompanying pre-funded warrants from august 2024 public offering, net of issuance costs of 12.2 million | 0 | -237,294 |
| Issuance of common stock and accompanying pre-funded warrants from june 2025 public offering, net of issuance costs of 15.7 million | -272,671 | - |
| Proceeds from stock option exercises | 12,789 | 8,237 |
| Proceeds from employee stock purchase plan | 1,112 | 1,112 |
| Payments on finance leases | 1,078 | 659 |
| Net cash provided by financing activities | 285,494 | 245,984 |
| Net increase in cash, cash equivalents and restricted cash | -7,313 | 215,586 |
| Cash and cash equivalents at beginning of period | 126,050 | - |
| Cash and cash equivalents at end of period | 118,737 | - |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)